BE898082A - Solution pour injection et procede pour sa preparation. - Google Patents

Solution pour injection et procede pour sa preparation. Download PDF

Info

Publication number: BE898082A
Authority: BE; Belgium
Prior art keywords: injection; solution; antirheumatic; substances; preparation
Prior art date: 1982-10-27

Application number

BE0/211771A

Other languages

English (en)

French (fr)

Original Assignee

Gerot Pharmazeutika

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-10-27

Filing date

1983-10-26

Publication date

1984-02-15

1983-10-26 Application filed by Gerot Pharmazeutika filed Critical Gerot Pharmazeutika

1984-02-15 Publication of BE898082A publication Critical patent/BE898082A/fr

Links

238000002347 injection Methods 0.000 title claims abstract description 13
239000007924 injection Substances 0.000 title claims abstract description 13
239000000243 solution Substances 0.000 title claims description 20
238000002360 preparation method Methods 0.000 title claims description 8
238000000034 method Methods 0.000 title claims description 6
239000003435 antirheumatic agent Substances 0.000 claims abstract description 15
239000002904 solvent Substances 0.000 claims abstract description 12
230000003356 anti-rheumatic effect Effects 0.000 claims abstract description 11
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 7
239000007864 aqueous solution Substances 0.000 claims abstract description 6
238000007918 intramuscular administration Methods 0.000 claims abstract description 4
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 claims abstract description 3
239000003246 corticosteroid Substances 0.000 claims abstract description 3
229960000581 salicylamide Drugs 0.000 claims abstract description 3
239000000126 substance Substances 0.000 claims abstract 4
239000013543 active substance Substances 0.000 claims description 11
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
239000003589 local anesthetic agent Substances 0.000 claims description 3
150000003218 pyrazolidines Chemical class 0.000 claims description 2
150000001768 cations Chemical class 0.000 claims 1
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000011782 vitamin Substances 0.000 description 6
229940010007 cobalamins Drugs 0.000 description 5
150000001867 cobalamins Chemical class 0.000 description 5
235000000639 cyanocobalamin Nutrition 0.000 description 5
239000011666 cyanocobalamin Substances 0.000 description 5
229960002104 cyanocobalamin Drugs 0.000 description 5
239000012154 double-distilled water Substances 0.000 description 5
229940088594 vitamin Drugs 0.000 description 5
229930003231 vitamin Natural products 0.000 description 5
235000013343 vitamin Nutrition 0.000 description 5
150000003722 vitamin derivatives Chemical class 0.000 description 5
229960003957 dexamethasone Drugs 0.000 description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 4
229960000194 kebuzone Drugs 0.000 description 4
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
229930003779 Vitamin B12 Natural products 0.000 description 3
230000003902 lesion Effects 0.000 description 3
229960004194 lidocaine Drugs 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000011715 vitamin B12 Substances 0.000 description 3
235000019163 vitamin B12 Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
-1 N-methylpyrrolidone Chemical class 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229930003270 Vitamin B Natural products 0.000 description 1
210000005221 acidic domain Anatomy 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002301 glucosamine derivatives Chemical class 0.000 description 1
244000000053 intestinal parasite Species 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000012797 qualification Methods 0.000 description 1
RLISWLLILOTWGG-UHFFFAOYSA-N salamidacetic acid Chemical compound NC(=O)C1=CC=CC=C1OCC(O)=O RLISWLLILOTWGG-UHFFFAOYSA-N 0.000 description 1
229950000417 salamidacetic acid Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
OEQSACUVTKYXIR-UHFFFAOYSA-M sodium;2-(2-carbamoylphenoxy)acetate Chemical compound [Na+].NC(=O)C1=CC=CC=C1OCC([O-])=O OEQSACUVTKYXIR-UHFFFAOYSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BE0/211771A 1982-10-27 1983-10-26 Solution pour injection et procede pour sa preparation. BE898082A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AT392982A AT376879B (de)	1982-10-27	1982-10-27	Verfahren zur herstellung einer injektionsloesung

Publications (1)

Publication Number	Publication Date
BE898082A true BE898082A (fr)	1984-02-15

Family

ID=3557346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE0/211771A BE898082A (fr)	1982-10-27	1983-10-26	Solution pour injection et procede pour sa preparation.

Country Status (7)

Country	Link
AT (1)	AT376879B (de)
BE (1)	BE898082A (de)
CH (1)	CH657525A5 (de)
DE (1)	DE3337304A1 (de)
FR (1)	FR2535205B1 (de)
LU (1)	LU85040A1 (de)
NL (1)	NL8303549A (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3437232A1 (de) *	1984-10-10	1986-04-17	Mack Chem Pharm	Stabilisierte injektionsloesungen von piroxicam
US5962536A (en) *	1998-07-31	1999-10-05	Komer; Gene	Injectable propofol formulations
DE102007012644A1 (de)	2007-03-16	2008-09-18	Bayer Healthcare Ag	Stabilisierung von Vitamin B12
CU24142B1 (es) *	2010-10-29	2015-12-23	Troikaa Pharmaceuticals Ltd	Composiciones nasales de vitamina b12

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1053736B (de) *	1956-03-02	1959-03-26	Konink Nl Gist & Spiritusfabri	Verfahren zur Erhoehung der Loeslichkeit therapeutisch wirksamer Stoffe in Wasser
DE1249453B (de) *	1963-10-14
GB1076670A (en) *	1964-11-02	1967-07-19	Chugai Pharmaceutical Co Ltd	A stabilised aqueous hydroxo cobalamin solution
DE2103387C3 (de) *	1971-01-26	1982-05-06	Johann G.W. Opfermann & Sohn, 5070 Bergisch-Gladbach	Verwendung des Hydrochlorids von Glukosamin zur Herstellung von pharmazeutischen Präparaten
AU485607B2 (en) *	1972-12-04	1975-04-24	Ici Australia Limited	Compositions
DE2522187C2 (de) *	1975-05-17	1977-10-28	Byk Gulden Lomberg Chem Fab	Verwendung von Cystein oder dessen Säureadditionssalz und Natriumdisulfit zur Stabilisierung von injizierbaren, einen pH-Wert zwischen 7 und 9 aufweisenden, Vitamin B tief 12 und nichtsteroidal Entzündungshemmer enthaltenden Arzneimitteln
JPS54151668A (en) *	1978-05-22	1979-11-29	Teijin Ltd	Production of fluffed fabric
LU80432A1 (de) *	1978-10-26	1979-03-19	Hoffmann K	Verfahren zum herstellen einer injektionsloesung,die mono-phenylbutazon enthaelt,und injektionsloesung,hergestellt nach diesem verfahren
JPS5675438A (en) *	1979-11-22	1981-06-22	Senjiyu Seiyaku Kk	Method for stabilizing aqueous solution of cyanocobalamin
JPS5675436A (en) *	1979-11-22	1981-06-22	Eisai Co Ltd	Solid pharmaceutical containing cobamamide or mecobalamin
NZ195881A (en) *	1980-12-19	1984-08-24	W Lysaght	Pharmaceutical compositions containing cobalt compounds

1982
- 1982-10-27 AT AT392982A patent/AT376879B/de not_active IP Right Cessation
1983
- 1983-10-07 LU LU85040A patent/LU85040A1/xx unknown
- 1983-10-13 DE DE19833337304 patent/DE3337304A1/de not_active Withdrawn
- 1983-10-14 NL NL8303549A patent/NL8303549A/nl not_active Application Discontinuation
- 1983-10-21 FR FR8316819A patent/FR2535205B1/fr not_active Expired
- 1983-10-26 BE BE0/211771A patent/BE898082A/fr not_active IP Right Cessation
- 1983-10-26 CH CH580983A patent/CH657525A5/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
CH657525A5 (de)	1986-09-15
ATA392982A (de)	1984-06-15
DE3337304A1 (de)	1984-05-03
LU85040A1 (de)	1984-03-22
FR2535205B1 (fr)	1987-02-06
NL8303549A (nl)	1984-05-16
AT376879B (de)	1985-01-10
FR2535205A1 (fr)	1984-05-04

Legal Events

Date

Code

Title

Description

1993-04-30

RE

Patent lapsed

Owner name: GEROT-PHARMAZEUTIKA G.M.B.H.

Effective date: 19921031

Publication	Publication Date	Title
DE69519667T2 (de)	2001-04-26	Verfahren zur stabilisierung von duocarmycinderivaten
KR860001503B1 (ko)	1986-09-30	이버멕틴의 수용화 방법
DE3872029T2 (de)	1992-12-03	Rektal absorbierbare form von l-dopa.
FR2853547A1 (fr)	2004-10-15	Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame, et procede pour leur production
FR2547727A1 (fr)	1984-12-28	Compositions pharmaceutiques
JPH06263630A (ja)	1994-09-20	ビタミンａ類可溶化点眼剤
WO2006126214A2 (en)	2006-11-30	Injectable compositions and process for preparation of such compositions
EP1285667A2 (de)	2003-02-26	Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
EA008908B1 (ru)	2007-08-31	Инъецируемый жидкий состав парацетамола
US8450356B2 (en)	2013-05-28	Pharmaceutical composition
CH670448A5 (de)	1989-06-15
BE898082A (fr)	1984-02-15	Solution pour injection et procede pour sa preparation.
JP2021519817A (ja)	2021-08-12	液体薬学的製剤
US4842856A (en)	1989-06-27	Parenteral solution
JP3242622B2 (ja)	2001-12-25	非ステロイド系抗炎症薬の非経口で水混和性の非濃色注射可能組成物
FR2772272A1 (fr)	1999-06-18	Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
EP0996437B1 (de)	2001-05-16	Halbfeste pharmazeutische zubereitungen enthaltend dexketoprofen-trometamol
US3499088A (en)	1970-03-03	Stable aqueous solutions of coenzyme q with a polyoxyethylene hydrogenated castor oil and propylene glycol and process for the manufacture thereof
HU177873B (en)	1982-01-28	Further developped process for preparing an aequous solution containing a complex of n-/3-chloro-4-/4-chloro-phenoxy/-phenyl/-2-hydroxy-3,5-diiodo-benzamide with polyvinyl-pyrrolidone
US20250340579A1 (en)	2025-11-06	Methods for cobinamide synthesis
BE1004051A4 (fr)	1992-09-15	Solution injectable et procede pour la preparer.
JP2001163776A (ja)	2001-06-19	安定化された液剤
EP0236822B1 (de)	1990-12-27	Stabile injizierbare Arzneiformulierung des 1,4-Dihydroxy-5,8-bis((2-(hydroxyäthylamino)-äthyl)amino)anthrachinondihydrochlorids
JPH0366617A (ja)	1991-03-22	静脈内投与用フエニトインナトリウム製剤
JPS5821888B2 (ja)	1983-05-04	スイセイラフオキサニドセイザイ